US venture capital firm New Enterprise Associates has appointed David M Mott as general partner. Mott will focus on biotechnology and specialty pharmaceutical investing within NEA's East Coast healthcare practice.
Prior to joining NEA, Mott was president and CEO of MedImmune, subsidiary of AstraZeneca, and executive vice president of AstraZeneca. He joined MedImmune in 1992 and also founded the company's venture capital subsidiary, MedImmune Ventures, in 2002.
'Dave has long been a galvanising force in the biotechnology industry - he is a global thought leader who has contributed enormously to innovation in life sciences,' said Peter J Barris, managing general partner of NEA. 'His broad sector expertise and strong ties within the biopharma community add substantial depth to NEA's healthcare practice, and we are delighted to welcome him to the firm.'
Mott is currently a director of specialty pharmaceuticals company Shire and of antibiotic company Rib-x Pharmaceuticals.
NEA invests at all stages of a company's development, from seed stage to IPO. It has $8.5bn in capital under management.
No comments:
Post a Comment